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Carcinoma
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Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea 
The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from 
being predominantly cytokine-based treatment to the use of targeted agents, which in-
clude sorafenib, sunitinib, bevacizumab (plus interferon alpha [IFN-α]), temsirolimus, 
everolimus, pazopanib, and most recently, axitinib. Improved understanding of the mo-
lecular pathways implicated in the pathogenesis of RCC has led to the development 
of specific targeted therapies for treating the disease. In Korea, it has been 5 years since 
targeted therapy became available for mRCC. Thus, we now have broader and better 
therapeutic options at hand, leading to a significantly improved prognosis for patients 
with mRCC. However, the treatment of mRCC remains a challenge and a major health 
problem. Many questions remain on the efficacy of combination treatments and on the 
best methods for achieving complete remission. Additional studies are needed to opti-
mize the use of these agents by identifying those patients who would most benefit and 
by elucidating the best means of delivering these agents, either in combination or as 
sequential single agents. Furthermore, numerous ongoing research activities aim at 
improving the benefits of the new compounds in the metastatic situation or their appli-
cation in the early phase of the disease. This review introduces what is currently known 
regarding the fundamental biology that underlies clear cell RCC, summarizes the clin-
ical evidence supporting the benefits of targeted agents in mRCC treatment, discusses 
survival endpoints used in pivotal clinical trials, and outlines future research 
directions.
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INTRODUCTION
The resistance of renal cell carcinoma (RCC) to the tradi-
tional cytotoxic chemotherapy is now well established. For 
many years, the mainstream therapy modality of meta-
static renal cell carcinoma (mRCC) was based on cyto-
kine-mediated approaches using either interferon alpha 
(IFN-α) or interleukin-2 (IL-2) or both [1]. The results with 
these agents were less than satisfactory because they pro-
duced objective response rates on the order of only 10 to 
20%, with long-term durable responses in 5 to 7% of cases, 
at least for high-dose IL-2 [2,3]. Since the availability of in-
formation regarding the aberrant activities of signal trans-
duction pathways in RCC, specific molecular targets for po-
tential therapies have been identified and analyzed phar-
macologically in a variety of in vitro and preclinical studies. 
As a result, the treatment of mRCC has dramatically 
changed in recent years. This has been driven by two groups 
of targeted agents: namely, vascular endothelial growth 
factor (VEGF)-targeted therapies and mammalian target 
of rapamycin (mTOR) inhibitors [4]. Since 2005, seven tar-
geted agents have been approved by regulatory authorities 
in the United States (US) and Europe (Axitinib is newly ap-
proved by the US Food and Drug Administration) for vari-
ous uses in advanced RCC or mRCC patients. However, de-
spite these advancements in treatment modalities, there Korean J Urol 2012;53:217-228
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are many limitations when it comes to the treatment of 
mRCC.
The objectives of this article were to review the clinical 
evidence supporting the benefits of these agents, introduce 
the treatment guidelines, and identify limitations. Fur-
thermore, future research directions with these targeted 
therapies are discussed. 
EPIDEMIOLOGY OF RCC
RCC is the most common renal tumor and accounts for 3% 
of all adult cancers [5]. The incidence and mortality of renal 
malignancies have been on the rise worldwide over the past 
more than 30 years [6], particularly in the Western world, 
where kidney cancer has been among the highest of the tu-
mors with an upward trend in incidence [6,7]. According 
to the recent report of the Korea Central Cancer Registry, 
RCC accounted for 1.8% of Korean cancers in 2008 [8]. Since 
then, the incidence of RCC in Korea has shown a steady 
increase.
Rising incidence rates are partly attributable to im-
provements in diagnostic imaging, but better detection 
does not explain the continued high number of advanced 
tumors and the increase in tumor size-speciﬁc mortality 
among RCC patients [7]. Surgery remains the mainstay 
therapy modality for those who present with clinically lo-
calized tumors and is an effective cure for the majority of 
patients. However, at least one-third of patients are diag-
nosed with metastases and an additional 20 to 40% of pa-
tients develop metastases after radical nephrectomy with 
curative intent [9-11]. The outcome of patients with mRCC 
is poor. The 5-year survival rate of RCC patients with meta-
static lesions is 0 to 20% [12-14] and is 25 to 50% even if 
the metastatic lesion is solitary and can be completely re-
sected [15-17].
IMMUNOTHERAPY FOR mRCC
Previously, systemic treatment was limited to cytokine 
therapy with IL-2 or IFN-α, because mRCC is largely re-
sistant to chemotherapy [1]. Cytokine therapy is based on 
the rationale that stimulation of the immune system kills 
cancer cells. However, this modality in patients with 
mRCC is associated with low rates of response yet high 
rates of toxicity in the first-line setting [1]. In the sec-
ond-line setting (in patients who have progressed on one 
cytokine), even fewer responses are observed, and toxicity 
remains similar to that of the first-line use [18]. In addition, 
patients' median survival period is only about 13 months 
[19-21].
However, high-dose IL-2 remains the only agent with 
proven efficacy in producing complete and partial re-
sponses in patients with mRCC [21-23]. Furthermore, de-
spite the use of a single-agent interferon, which has de-
creased significantly since the introduction of targeted 
therapy, it remains in the frontline setting in combination 
with bevacizumab as a result of 2 large phase III trials 
[24,25]. Lastly, improved understanding of immune regu-
lation has led to the advancement of targeted immuno-
therapy using immune checkpoint inhibitors that have 
shown promising activity and that are moving forward in 
clinical development [26].
MECHANISMS OF TARGETED THERAPY IN mRCC
There are at least 5 histological forms of RCC. The most 
prevalent is the clear cell type, which accounts for 75% of 
cases [27,28]. Clear cell RCC is characterized by inacti-
vation of a crucial tumor-suppressor gene, known as von 
Hippel Lindau (VHL) [29,30]. Understanding the biologi-
cal processes that underlie the clear cell type RCC, in par-
ticular, the central role played by the VHL-hypoxia-in-
ducible factor (HIF)-VEGF axis, is important. This is be-
cause the various members of this cascade are the ther-
apeutic targets for most of the agents currently used in the 
management of clear cell type RCC. The concept of target-
ing these specific signaling molecules is the fundamental 
underpinning of the so-called “targeted therapies.” This 
principle has resulted in two fundamental ideologies that 
are nevertheless interrelated. These two principles under-
lie the categories of targeted therapeutics, i.e., those that 
block the VEGF pathway and those that block the mTOR 
pathway.
The typical mechanism of targeted therapy is shown in 
Fig. 1 [28]. VHL encodes the VHL protein. If VHL is in-
activated, a defective VHL protein is produced and HIF is 
not degraded. Activated HIF then translocates into the nu-
cleus and leads to the transcription of a wide repertoire of 
genes, including VEGF, platelet-derived growth factor 
(PDGF) [31], and transforming growth factor alpha [32], 
which have a central role in tumor angiogenesis and 
progression. Activation of the mTOR pathway also in-
creases HIF levels [33]. This leads to increased tran-
scription of genes, such as VEGF and PDGF, that control 
cell proliferation, glucose uptake, and angiogenesis [33]. 
Thus, increased HIF expression can promote angiogenesis 
in tumors.
EFFICACY OF TARGETED THERAPY IN mRCC
The targeted agents approved in the United States for the 
treatment of mRCC are sorafenib, sunitinib, bevacizumab 
(in combination with IFN-α), temsirolimus, everolimus, 
pazopanib, and, recently, axitinib. Table 1 summarizes the 
key efficacy data from the pivotal trials for these agents. 
Before the advent of targeted therapies, patients with 
mRCC treated with cytokines showed a median survival 
of 10 months [34]. Sunitinib, bevacizumab, and temsir-
olimus were compared with IFN-α in treatment-naïve pa-
tients and were found to be superior. In addition, sorafenib, 
everolimus, and pazopanib were shown to be superior to 
placebo in their deﬁning trials, although the intent of many 
of these latter protocols was to focus on the patients who 
had already failed a cytokine or anti-VEGF therapy [24,25, Korean J Urol 2012;53:217-228
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FIG. 1. Biological pathways and therapeutic targeted agents for renal cell carcinoma. Reprinted from Rini BI, Atkins MB, Lancet 
Oncol 2009;10:992-1000, with permission of Elsevier [28].
TABLE 1. Targeted agents for metastatic renal cell cancer (approved): key results of phase III study
Agent Setting No. ORR (%)
DCR
a (%)
CR＋PR＋SD
Median PFS 
(mo)
Median OS (mo)
Sunitinib vs. IFN-α [43]
Temsirolimus vs. IFN-α [41]
Bevacizumab＋IFN-α vs. 
placebo＋IFN-α 
(AVOREN) [24]
Bevacizumab＋IFN-α vs. 
IFN-α (CALBG 90206) [25]
Pazopanib vs. placebo [39]
Sorafenib vs. placebo [42]
Everolimus vs. placebo [36]
Axitinib vs. sorafenib [40]
1st-line
1st-line
Poor risk
1st-line
1st-line
1st-line
2nd
2nd-line
2nd-line
2nd-line
750
626
649
732
233
202
903
416
723
31 vs. 6
c
8.6 vs. 4.8
31 vs. 13
c
26 vs. 13
c
32 vs. 4
c
29 vs. 3
c
10 vs. 2
c
1.8 vs. 0
19 vs. 9
c
0＋31＋48 vs. 0＋6＋49
32.1 vs. 15.5
CB
b (OR＋SD ≥24 wk)
1＋30＋46 vs. 2＋11＋50
-
＜1＋30＋38 vs. 0＋3＋41
＜1＋10＋74 vs. 0＋2＋53
0＋27＋67 vs. 0＋0＋32
0＋19＋50 vs. 0＋9＋54
11.0 vs. 5.1
c
3.8 vs. 1.9
c
10.2 vs. 5.4
c
8.5 vs. 5.2
c
11.1 vs. 2.8
c
7.4 vs. 4.2
c
5.5 vs. 2.8
c
4.9 vs. 1.9
c
6.7 vs. 4.7
c
26.4 vs. 21.8
26.4 vs. 20.0
c (censored)
10.9 vs. 7.3c
23.3 vs. 21.3
18.3 vs. 17.4
22.9 vs. 20.5
17.8 vs. 15.2
17.8 vs. 14.3
c (censored)
14.8 vs. 14.4
NA
ORR, objective response rate; SD, stable disease; PFS, progression-free survival; OS, overall survival; IFN-α, interferon alpha; 
AVOREN, Avastin and Roferon in Renal Cell Carcinoma; CALBG, Cancer and Leukemia Group B; NA, not available.
aDCR (disease control rate), CR (complete response)＋PR (partial response)＋SD (stable disease) ≥3 mo, 
bCB, clinical benefit; OR, 
objective response (CR＋PR), 
cStatistically significant.
35-39]. In a recent study, as a second-line use, axitinib was 
found to be superior when compared with sorafenib [40].
An improvement in overall survival (OS) provides the 
most convincing evidence that a new therapy is superior 
to the existing standard modality. Only temsirolimus (for 
the patient with “poor-risk” RCC) had led to improved OS 
in randomized phase III trials [41]. However, other agents, 
including sunitinib, sorafenib, and pazopanib, are clearly 
active in RCC and constitute the comparator arm in several 
ongoing studies. Owing to the crossover of the patients and Korean J Urol 2012;53:217-228
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TABLE 3. Evidence-based clinical guidelines for systemic therapy for metastatic renal cell carcinoma
Setting
MSKCC risk
or prior treatment
Histology
Recommended (option)
NCCN
a EAU
b
First-line
Second-line
Good or intermediate risk
Poor risk
Prior cytokine
Prior VEGFRi
Prior mTORi
Clear cell
Non-clear cell
Clear cell
Non-clear cell
Sunitinib
Bevacizumab＋IFN-α
Pazopanib (HD IL-2) (sorafenib)
Clinical trial (sorafenib) (sunitinib) 
(temsirolimus)
Temsirolimus
Temsirolimus
Sorafenib
Sunitinib
Pazopanib (temsirolimus) 
(bevacizumab)
Everolimus (sorafenib) (sunitinib) 
Clinical trial
Sunitinib
Bevacizumab＋IFN-α
Pazopanib (HD IL-2)
-
Temsirolimus
-
Sorafenib 
Pazopanib (sunitninb) 
(temsirolimus)
Everolimus
Clinical trial
MSKCC, Memorial Sloan-Kettering Cancer Center; NCCN, National Comprehensive Cancer Network; EAU, European Association 
of Urology; IFN-α, interferon alpha; HD, high-dose; IL-2, interleukin-2; VEGFRi, vascular endothelial growth factor receptor inhibitor; 
mTORi, mammalian target of rapamycin inhibitor.
a: NCCN: Kidney Cancer, NCCN 2012 Clinical Practice Guidelines in Oncology V.1. 2012, Cat 1 & 2A, 
b: EAU: Guideline on Renal Cell 
Carcinoma 2010, Grade A.
TABLE 2. Results of targeted therapy for metastatic renal cell cancer (RCC) in Korea
Pivotal phase 
III study [37]
Hong et al. 
[75]
Yoo et al. 
[76]
Hwang et al. 
[77]
Kim et al. 
[44]
Lee et al. 
[78]
Han et al. [79]
Agent
Total no. of patients
Median age (yr)
Clear cell RCC
Patient with lung meta
MSKCC 0 (favorable)
MSKCC 1,2 (intermediate)
MSKCC ≥3 (poor)
Median PFS (mo)
Median OS (mo)
Objective response
Complete response
Partial response
Stable disease
Disease control rate
Sunitinib
375
  62
  375 (100)
292 (78)
143 (38)
209 (56)
23 (6)
  11
     26.4
137 (37)
  1 (1)
136 (36)
176 (47)
313 (81)
Sunitinib
76
   57.5
65 (85.5)
56 (73.7)
  7 (11.6)
47 (78.3)
6 (10)
     7.2
   22.8
21 (27.6)
1 (1.3)
20 (26.3)
43 (56.6)
64 (84.2)
Sunitinib
65
58
55 (85)
48 (74)
14 (21)
20 (31)
28 (43)
   11.8
   22.8
23 (43)
0 (0)
23 (43)
23 (43)
46 (86)
Sunitinib
21
   63.9
21 (100)
15 (71.4)
  4 (19.0)
10 (47.6)
  7 (33.3)
   13.4
   28.1
11 (52.4)
1 (4.8)
10 (47.6)
  7 (33.3)
18 (85.7)
Sunitinib
132
57.0
109 (82.6)
103 (78.0)
35 (30.4)
61 (53.0)
19 (16.5)
  8.2
23.1
45 (34.1)
2 (1.5)
43 (32.6)
59 (44.7)
104 (80.3)
Sunitinib, 
Sorafenib, 
Pazopanib
88
56
   71 (81.0)
65 (74)
-
-
  88 (100)
     5.0
     9.3
19 (22)
1 (1)
18 (21)
29 (34)
48 (56)
Sunitinib, 
Sorafenib
46
59
37 (80.4)
-
-
-
-
-
-
14 (30.4)
0 (0)
14 (30.4)
17 (40.0)
31 (70.4)
Values are presented as number (%).
MSKCC, Memorial Sloan-Kettering Cancer Center risk group; PFS, progression-free survival; OS, overall survival.
a widespread use of active agents in patients who progress 
on their assigned therapy, the OS analysis in randomized 
trials may be confounded. In a recent update, with censor-
ing of crossover data, the median overall survival with su-
nitinib and sorafenib was significantly longer than for their 
respective control groups [42,43]. Therefore, the OS benefit 
of these drugs seems to be relatively clear.
Currently, several retrospective studies and one pro-
spective trial using tyrosine kinase inhibitors (TKIs) have 
been published in Korea (Table 2). According to these stud-
ies, TKIs, especially sunitinib, seem to be efficacious in a 
manner similar to or even better than in Western patients 
with slightly different treatment-related adverse events, 
such as a high incidence of hematological toxicities [44].
 Korean J Urol 2012;53:217-228
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TABLE 4. Coverage of National Health Insurance for metastatic RCC in Korea
No. Systemic agent Treatment target Treatment setting
1
2
3
4
5
6
7
8
Aldesleukin (IL-2)
Aldesleukin＋IFN-α
Aldesleukin＋IFN-α＋5FU
Sunitinib
Sorafenib
Pazopanib
Temsirolimus
a
Everolimus
Stage 4 RCC
Stage 4 RCC
Stage 4 RCC
Metastatic or recurred
Metastatic or recurred
Metastatic or recurred
Metastatic or recurred
Metastatic or recurred
  (sunitnib or sorafenib or pazopanib failure)
First line or more
First line or more
First line or more
First line or more
First line or more
First line or more
First line
Second line or more
RCC, renal cell carcinoma; IL-2, interleukin-2; IFN-α, interferon alpha; 5FU, 5-fluorouracil.
a: Only for non-clear cell carcinoma or poor risk clear cell carcinoma.
CURRENT GUIDELINES FOR THE TREATMENT 
OF mRCC
The treatment guidelines for mRCC are experiencing a 
rapid evolution to incorporate the new molecular-targeted 
therapies that have been approved recently by the US and 
European regulatory authorities. Table 3 summarizes the 
current updated recommendations contained in the 
National Comprehensive Cancer Network (NCCN) and 
European Association of Urology (EAU) guidelines. 
In terms of clear cell mRCC, the NCCN guidelines (ver. 
1.2012) recommend a number of options for first- and sec-
ond-line treatment of mRCC. For first-line therapy, the 
recommended modalities for patients with a good or inter-
mediate prognosis are sunitinib, bevacizumab plus IFN-α, 
and pazopanib. Temsirolimus has a recommendation for 
the treatment of patients with poor-prognosis mRCC. In 
addition, the NCCN also suggests alternatives for selected 
patients in the first-line setting, such as high-dose IL-2 or 
sorafenib, temsirolimus, and enrollment in a clinical trial. 
For second-line therapy, everolimus is the only agent to 
have an NCCN category 1 recommendation for the treat-
ment of patients who have failed TKI treatment. Sorafenib, 
sunitinib, and pazopanib are recommended for the treat-
ment of patients after cytokine failure. For the treatment 
of patients after the failure of other TKIs, sorafenib, suniti-
nib, and pazopanib are also recommended as an alternative 
treatment (category 2B or 3). Temsirolimus is also consid-
ered as the treatment for patients after cytokine failure 
(category 2A) in addition to the treatment for patients after 
TKI failure (category 2B). The EAU guidelines also recom-
mend treatment options for patients with predominantly 
clear cell RCC. As a first-line therapy, sunitinib, bev-
acizumab plus IFN-α, and pazopanib are recommended for 
the treatment of low- and intermediate-risk patients. For 
the treatment of high-risk patients, temsirolimus is 
recommended. IFN-α monotherapy is no longer 
recommended. However, high-dose bolus IL-2 is recom-
mended as a first-line treatment for mRCC in patients with 
clear cell histology and good prognostic factors. As a sec-
ond-line therapy, everolimus has a recommendation for 
the treatment of patients after TKI failure; sorafenib and 
pazopanib are each recommended for the treatment of pa-
tients after cytokine failure; and enrollment in clinical tri-
als is recommended for the treatment of patients after 
mTOR inhibitor failure.
For patients with non-clear cell mRCC, enrollment in 
clinical trials of systemic therapy has been the preferred 
strategy. However, the 2012 NCCN guidelines provide 
first-line therapy recommendations for patients with 
non-clear cell mRCC. Temsirolimus has a category 1 rec-
ommendation for the treatment of patients with poor risk 
non-clear cell mRCC.
In Korea, sunitinib and sorafenib have been used as a 
first-line treatment for patients with clear cell mRCC un-
der the support of national health insurance since 2007. 
Furthermore, pazopanib has also been used since May 
2011. For the treatment of non-clear cell mRCC or clear cell 
mRCC, with poor risk group patients, national health in-
surance has reimbursed the use of temsirolimus since June 
2011. Most recently, everolimus was approved by the mul-
tidisciplinary committee for patients with sunitinib or sor-
afenib or pazopanib failure under insurance coverage. 
Table 4 shows the coverage of national health insurance in 
Korea for patients with mRCC. 
DRUG RESISTANCE AND TREATMENT 
STRATEGIES
Some patients are inherently resistant to these targeted 
agents. In addition, most, if not all, patients acquire resist-
ance over time. In general, the development of resistance 
has been observed after a median of 6 to 11 months of treat-
ment [28]. Complete or durable responses have only rarely 
been noted, necessitating chronic therapy for most 
patients. Several strategies emerge from the above consid-
erations regarding the mechanisms of resistance to the cur-
rently available therapeutics in mRCC. The ﬁrst involves 
the use of an agent that blocks a resistance mechanism. 
Such an agent could be used as a monotherapy at the time 
of resistance to targeted therapy, could be added to con-
tinued VEGF blockade at the time of resistance, or could Korean J Urol 2012;53:217-228
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TABLE 5. Prospective trials of sequential therapy (TKIs to TKIs/mTOR inhibitors)
Agent Phase Population N ORR
a (%) PFS
b (mo) OS
c (mo)
TKIs
Axitinib vs. sorafenib [40]
Sunitinib [51]
Axitinib [80]
Axitinib [81]
Sorafenib [82]
Sorafenib [49]
ABT-869 [83]
mTOR inhibitors
Everolimus vs. placebo [36]
Everolimus [84]
Temsirolimus＋bevacizumab [85]
Everolimus＋bevacizumab [86]
III
II
II
II
II
II
II
III
II
II
II
II
Sunitinib, bevacizumab＋IFN, 
Temsirolimus, or cytokine
Bevacizumab-refractory
Sorafenib-refractory
Sunitinib＋sorafenib
Bevacizumab or sunitinib-R
Sunitinib-refractory
Sunitinib-refractory
TKI-refractory
TKI-refractory
TKI-refractory
Sorafenib ＋/- sunitinib-refractory
717
62
62
14
31
52
53
416
26
37
30
19.4 vs. 9.4
23
22.6
  7
  3
  9.6
  9
2 vs. 0
  0
18
23
6.7 vs. 4.7
p＜0.0001
  7.1
  7.4
  7.1
308
  4
  5.4
4.9 vs. 1.9
p＜0.0001
  6.5＋
  5.3
  7.1
NA
11.8
13.6
11.5
NA
  8
NA
14.8 vs. 14.43
p=0.177
16.3＋
NA
NA
TKIs, tyrosine kinase inhibitors; mTOR, mammalian target of rapamycin; ORR, objective response rate; PFS, progression-free survival; 
OS, overall survival; INF, interferon; NA, not available.
be added initially in combination with VEGF blockade with 
the hope of delaying the onset of resistance. Alternatively, 
more eﬀective blockade of the initial target could involve 
increasing the dose of an existing agent or measuring the 
drug concentrations to ensure an adequate dosing, or alter-
natively, switching to an agent that more potently inhibits 
the target.
The current strategies to maximize the effectiveness of 
treatment are as follows.
1. Sequential therapy
Targeting different pathways may offer benefit in terms of 
overcoming resistance to individual agents. Sequential 
therapy has the potential to change mRCC into a chronic 
disease that can be managed for a long term through the 
administration of targeted agents in sequence. Although 
clinicians are currently using targeted agents in a sequen-
tial manner for patients with mRCC in practice, concerns 
remain regarding cross-resistance between the different 
agents. Thus, there are many questions regarding the opti-
mal sequence for obtaining maximum clinical benefit from 
the available targeted therapies. In addition, adequate 
management of treatment-related toxicity can allow pa-
tients to remain on treatment for long periods and can help 
to maximize the clinical benefit of targeted agents. Recen-
tly, strategies to manage treatment-related adverse events 
are being refined [45].
The first randomized phase III study to investigate se-
quential targeted therapy in mRCC showed clinical effi-
cacy for the sequence of sunitinib or sorafenib, followed by 
everolimus (RECORD-1) [36,46]. In this study, patients 
who had failed an earlier anti-VEGF therapy, 71% of whom 
had received sunitinib previously, were treated with either 
everolimus or placebo. The median progression-free sur-
vival (PFS) was 4.9 months vs. 1.9 months for those treated 
with everolimus or the placebo, respectively (hazard ratio, 
0.33; 95% confidence interval, 0.25 to 0.43; p＜0.01). Impro-
vements in PFS with everolimus relative to the placebo 
were observed across all Memorial Sloan-Kettering Can-
cer Center prognostic risk groups. 
In addition, sequential TKIs are also thought to be 
effective. Some retrospective studies have shown that pa-
tients who fail first-line therapy with sunitinib might bene-
fit from sorafenib treatment [47,48]. Di lorenzo et al. [49] 
confirmed these findings in a prospective phase II trial in 
which 77% of patients had failed sunitinib treatment and 
benefited from second-line sorafenib, with a median PFS 
of 16 weeks. Similar data also exist for sunitinib after sor-
afenib failure. Dudek et al. [50] revealed that patients who 
received sorafenib followed by sunitinib had a median du-
ration of stable disease of 20 weeks (median OS, 102 weeks; 
59% clinical benefit). Subsequently, it was also reported 
that second­line sunitinib showed efficacy in patients with 
an initial failure from bevacizumab [51]. The recently re-
ported AXIS phase 3 trial directly compared the efﬁcacy 
and safety of axitinib with the active comparator sorafenib 
in patients with mRCC who had failed one previous sys-
temic therapy [40]. Axitinib was shown to be more effective 
than sorafenib in patients who had progressed after pre-
vious treatment with sunitinib, bevacizumab＋IFN-α, 
temsirolimus, or cytokines. The AXIS trial was these pa-
tients’ first exposure to a VEGFR-TKI, whereas 54% of pa-
tients had received previous sunitinib. In the subgroup of 
AXIS patients who had received previous sunitinib, the 
median PFS was 4.8 months with axitinib and 3.4 months 
with sorafenib (p=0.011). Furthermore, the shorter me-
dian PFS observed in both treatment arms in the suniti-
nib-refractory patients relative to those who received cyto-
kines is suggestive of at least partial cross-resistance with 
sequential VEGF-targeted therapy. Table 5 summarizes 
the results of several prospective trials of sequential ther-
apy with TKIs to TKI/mTOR inhibitors. Korean J Urol 2012;53:217-228
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TABLE 6. Efficacy of treatment with a third-line TKI following treatment with sequential VEGFR-TKI→TOR inhibitor therapy
Sequence Design No.
Median PFS
1st line TKIs
(mo)
Median PFS
2nd line mTORi
(mo)
Median PFS
3rd line TKis
(mo)
ORR
n (%)
SD
n (%)
DCR
n (%)
OS
(mo)
TKIs→Eve→
TKIs [87]
Su→Various
→Su [52]
Su→mTORi
→So [88]
TKIs→Eve→
TKIs [89]
So→Eve→Su 
[90]
Su→Eve→So
TKIs→Eve→
Dov [91]
Retro
Retro
Retro
Retro
Retro
Pros
40
26
34
36
14
26
31
11.3
13.7
10
11.4
11.7
14.4
5.9
26
4 (Eve)/2 (Tem)
8.9
5.1
4.3
5.5
b (0.4-22.3)
7.2
d (1.2-28.5＋)
    4 (3-6)
8.2
9.1
3.9
5.5
4 (10)
5 (21)
8
e (23.5)
3 (8.6)
2 (3.4)
22
a (55)
17 (71)
  7 (20.5)
24 (68.6)
29 (49.2)
g
26 (65)
22 (92)
15 (44)
27 (77.1)
11.3
c (0.8-22.3)
NA
    7
h (6-10)
29.1
f
21.9
22.8
11.8
i
TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor; mTORi, mammalian target of rapamycininhibitor; 
PFS, progression-free survival; ORR, objective response rate; SD, stable disease; DCR, disease control rate; OS, overall survival; Eve, 
everolimus; Tem, temsirolimus; Su, sunitinb; So, sorafenib; Dov, dovitinib; Retro, retrospective; Pros, prospective.
a: SD≥3 mo, DCR: PR＋SD, 
b: PFS: treatment of sorafenib ＋/-, PFS after everolimus 3.7 vs. 11.3 mo, p=0.036 in uni-variate analyses, 
c: OS: from start of third-line TKIs, OS: PFS first-line VEGF treatment ≥6 mo vs. ＜6 mo, OS 53.4 vs.19.3 mo, p=0.002, 
d: Median PFS: 
sunitinib rechallenge interval＞6 mo vs. ≤6 mo, 16.5 vs. 6.5 mo, p=0.3, 
e: Response rate: first-line sunitinib responder vs. non-responder, 
47% vs. 0%, p=0.0027, 
f: OS: everolimus→sunitinib vs. everolimus→sorafenib=30.5 mo vs. 17.6 mo (p=0.102), 
g: SD: SD≥2 mo 29 (49.2%), 
SD≥4 mo 16 (27.1%), 
h: OS: from start of sorafenib treatment, 
i: OS: from start of dovitinib treatment.
Recently, several studies evaluating the efﬁcacy of a sec-
ond VEGFR-TKI, following a VEGFR-TKI→mTOR in-
hibitor treatment sequence, have been reported with en-
couraging results (Table 6). These results suggest that re-
introduction of a VEGFR-TKI following progression on a 
VEGFR-TKI-mTOR inhibitor treatment sequence is an ef-
fective strategy. However, patients appear to derive a less-
er degree of clinical beneﬁt from VEGFR-TKI repeat chal-
lenge than that obtained in the ﬁrst-line setting, which sug-
gests at least partial cross-resistance. Interestingly, tran-
sient resistance to the same agent has also been observed. 
In a recent retrospective review of 23 patients, repeat chal-
lenge with sunitinib in patients with disease progression 
on sunitinib and other therapies resulted in 5 patients 
(22%) achieving a partial response and 17 patients (74%) 
achieving stable disease [52]. Repeat challenge was asso-
ciated with a median PFS of 7.2 months compared with 13.7 
months on the initial treatment (p=0.04). The results de-
scribed here indicate the potential for re-treating with an 
agent, despite the occurrence of resistance from the first 
treatment, and have implications for achieving a con-
tinuum of treatment in these patients. So far, no therapies 
are approved for the third-line treatment of mRCC. In clin-
ical practice, however, a strategy that is growing is the re-
introduction of a VEGFR-TKI following the progression on 
a VEGFR-TKI and an mTOR inhibitor.
2. Combination therapy
The effectiveness of combination therapies is much more 
promising than that of single targeted therapies. It is hoped 
that combination therapies may induce better responses 
because they interfere with sequential steps in a single 
pathway or attack a tumor from two sides. However, for any 
potential clinical benefit, there must be a balance between 
the potential increases in toxicity associated with combin-
ing therapeutic agents. Because most combination data to 
date are preliminary, no combination can be said to fulfill 
this requirement. To determine clinical applicability, fur-
ther studies are required of targeted agent combinations, 
if any. It is also important to consider the therapeutic op-
tions that are possible or available following the use of com-
bination-targeted agent therapy [53].
3. Adjuvant therapy
Adjuvant therapy has been used in the treatment of several 
malignancies with favorable results. To date, however, no 
medical therapies have been shown to improve outcomes 
in RCC when used in the adjuvant setting [54-56]. In the 
field of targeted therapy, the S-TRAC, ASSURE, and 
SORCE trials are ongoing for patients at high risk of re-
currence (Table 7). The results of these trials are eagerly 
awaited to determine the role of targeted therapy in the ad-
juvant setting.
4. Neoadjuvant (presurgical) therapy
Nowadays, we have yet to understand how targeted agents 
can be integrated with surgical approaches to maximize 
clinical beneﬁt [57-60]. Cytokines do not affect the primary 
tumor. However, targeted therapies have an effect on the 
primary tumor, even in the absence of metastatic disease.Korean J Urol 2012;53:217-228
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TABLE 7. Ongoing adjuvant trials with targeted agents in renal cell carcinoma (RCC)
Treatment
Clinical trials 
identifier
No. Sponsor Start Projected completion
SORCE
Sorafenib vs. placebo
Sorafenib 1 vs. 3 yr 
(resected primary RCC at 
high/intermediate risk)
ASSURE
Sorafenib vs. placebo
Sunitinib vs. placebo 
(unfavorable RCC)
S-TRAC
Sunitinib vs. placebo 
(high risk RCC)
EVEREST
Everolimus vs. placebo 
(high risk RCC)
PROTECT
Pazopanib vs. placebo 
(high risk RCC)
NCT00492258
NCT00326898
NCT00375674
NCT01120249
VEG113387
1,656
1,923
   600
1,218
1,500
MRC/EORTC
ECOG
Pfizer
SWOG
GSK
June 2007
May 2006
July 2007
February 2010
November 2010
August 2012
April 2016
June 2017
August 2013
December 2012
SORCE, A phase III randomised double-blind study comparing Sorafenib with placebo in patients with Resected primary renal cell carcino-
ma at high or intermediate risk of relapse; RCC, renal cell carcinoma; ASSURE, Adjuvant Sunitinib versus Sorafenib versus Placebo in 
Patients with Resected Renal Cell Carcinoma; S-TRAC, Sunitinib Treatment of Renal Adjuvant Cancer; EVEREST, EVErolimus for Renal 
Cancer Ensuing Surgical Therapy, A phase III study; PROTECT, Patient Related Outcomes with Endeavor versus Cypher Standing Trial; 
MRC, Medical Research Council; EORTC, European Organization for Research and Treatment of Cancer; ECOG, Eastern Cooperative 
Oncology Group; SWOG, Southwest Oncology Group; GSK, Glaxo Smith Kline.
In locally advanced non-mRCC, Karakiewicz et al. [61] 
reported an atrial tumor thrombus that was downstaged 
to the level of the infrahepatic vena cava after two cycles 
of sunitinib. However, another study showed that only 4 of 
17 patients with advanced RCC taking sunitinib, without 
a previous nephrectomy, experienced partial responses in 
their primary tumors and 1 patient progressed [62]. Neoad-
juvant targeted therapy can only downstage or improve the 
resectability of the primary tumor or associated lesions in 
20 to 25% of patients [63]. To date, there are no established 
criteria for discriminating between patients who will and 
those who will not benefit from neoadjuvant setting.
Furthermore, it is not known which patients with mRCC 
might benefit from an upfront targeted therapy followed 
by cytoreductive nephrectomy [57,64]. To clarify these crit-
ical issues, several studies are ongoing. The CARMENA 
and EORTC trials will provide evidence­based information 
regarding the benefits and the timing of cytoreductive 
nephrectomy in the targeted therapy era. Also in Korea, the 
Korean Urological Oncology Society recently led a prospec-
tive trial of “neoadjuvant sunitinib treatment for meta-
static clear cell RCC” (NCT01069770).
Although studies have demonstrated the general toler-
ability of targeted agents, data are still limited on the safety 
of surgical resection following treatment with these 
agents, and several studies have shown increased peri-
operative complications after treatment [65,66].
5. Targeted therapy for non-clear cell RCC
Temsirolimus represents the only targeted therapy for 
which superior efficacy was confirmed in advanced non-clear 
cell RCC in a prospective and randomized fashion. In addi-
tion, Hudes et al. [67] demonstrated better responses in pa-
tients with advanced non-clear cell RCC than in patients 
with clear cell disease in their temsirolimus data, which 
suggests that temsirolimus is an excellent first­line option 
in patients with non-clear cell mRCC. Despite the absence 
of prospective data for the efficacy of sunitinib or sorafenib, 
several investigators have demonstrated the efficacy of 
these two agents in patients with non-clear cell mRCC 
[68-70]. These data indicate that targeted therapies are 
clearly effective in patients with non-clear cell mRCC. 
Therefore, we need to look at the results of large prospective 
studies in the future.
PRESENT AND FUTURE OF TARGETED THERAPY 
IN mRCC
All seven agents (sunitinib, sorafenib, temsirolomus, bev-
acizumab＋IFN-α, pazopanib, everolimus, and axitinib) 
have shown efﬁcacy and safety in phase III randomized 
controlled clinical trials. However, mRCC patients have to 
undergo chronic treatment, because targeted therapies 
rarely achieve durable and complete remissions. Drug re-
sistance is the underlying reason for the growth and spread 
of tumors in the presence of systemic treatment. Further-Korean J Urol 2012;53:217-228
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more, it remains the main barrier against long-term tumor 
control. In general, better tolerance of the targeted thera-
pies than of chemotherapies is experienced by cancer 
patients. Nevertheless, the targeted agents still act as cyto-
toxic substances in a broader sense and can, therefore, 
cause several side effects that must not be neglected 
[71,72].
One therapy modality is not likely to benefit all patients, 
but rather a therapy modality is indicated on an individual, 
case-by-case basis. Treatment should be tailored to meet 
individual circumstances and needs, and achieving this is 
a considerable clinical challenge. Thus, many investiga-
tors emphasize the value of clinical judgment and experi-
ence to support treatment decisions for an individual [73]. 
Most patients today will receive several targeted therapies 
in a treatment sequence. Before starting first-line therapy, 
the whole potential therapeutic sequence should be consid-
ered for the individual patient.
An optimal balance between quality of life and prolonga-
tion of survival will only be achieved by considering both 
the benefits and the risks of the new targeted therapies 
[74]. We must overcome several treatment challenges to 
maximize the potential of targeted agents, and these in-
clude the identification of predictive molecular markers, 
drug resistance, the identification of the most effective se-
quence or combination of targeted agents, efficient clinical 
trial design, and the provision of cost-effective access to 
treatment for all patients with mRCC.
The development of targeted agents has substantially 
improved the prognosis of patients with mRCC. To further 
these advances, the following assignments are proposed for 
the future [53]. Identifying and optimizing the most appro-
priate sequence or combination of agents should be consid-
ered first. Second, overcoming drug resistance through 
newer agents or sequential or combination therapies 
should be addressed. Third, imaging techniques as pre-
dictive markers for efficacy should aim to minimize the 
treatment time for those patients without response to a 
particular agent. Fourth, molecular biomarkers should be 
developed to better identify the patients who are likely to 
benefit from a particular agent. Fifth, appropriate clinical 
trial designs and statistical methods to test new therapies 
should be developed.
CONCLUSIONS
Since the advent of targeted therapies, the modality of 
mRCC treatment has changed and the OS for these pa-
tients is now greater than 2 years in prospective studies. 
Currently, the first-line standard of care for patients with 
clear cell mRCC includes sunitinib, bevacizumab combina-
tion with IFN-α, pazopanib, and temsirolimus, all of which 
are options for patients with high­risk characteristics. 
Everolimus has proven efficacy as a second-line targeted 
therapy. The sequential use of targeted therapies can im-
prove PFS and OS. Additional progression-free survival 
benefits might be derived from cytoreductive nephrectomy 
while we await for the results of ongoing phase III trials. 
However, we have much work to be completed. As more in-
formation regarding mechanisms of disease and drug re-
sistance becomes available, new targets, new targeted 
agents, and new combinations will be studied with the goal 
of providing maximal efficacy with manageable toxicity. 
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